CommercialPrior AuthMedium impact
Inhaled Antibiotics for Cystic Fibrosis
Blue Cross & Blue Shield of Mississippi·MS · Pulmonology, Pediatrics·Medical Policy
We identified it
Jun 20, 2026
Summary
New prior authorization policy for inhaled antibiotics used in cystic fibrosis treatment, covering Cayston, Kitabis Pak, TOBI, and TOBI Podhaler. Prior authorization is required for all these medications with specific age, diagnosis, and clinical criteria that must be met for approval.
Action Required
Immediately: Billing team must update system to require prior authorization for all inhaled antibiotic prescriptions for cystic fibrosis patients (Cayston, Kitabis Pak, TOBI, TOBI Podhaler). Providers must verify patient age requirements (6+ for tobramycin, 7+ for aztreonam), confirm cystic fibrosis and Pseudomonas aeruginosa diagnosis, and ensure FEV1 levels meet criteria before prescribing. Claims will be denied without prior authorization approval.